• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Rachel Jimenez: Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable

Video

Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.

Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.

Transcript

How prevalent is cardiac toxicity in breast cancer, and what are some examples of the short-term versus long-term impact?

The risk of cardiac toxicity and the nature of cardiac toxicity in breast cancer is quite variable and it depends a lot on the patient’s baseline risk factors as well as what specific therapies they receive. So, we see different types of short- and long-term side effects based on the specific type of therapy that a patient receives for their breast cancer.

For example, as a radiation oncologist, my patients will receive radiotherapy that could expose the heart to radiation, and studies have suggested that in the short term that can cause pericarditis or other pericardial diseases and in the long term could cause coronary artery disease or heart failure.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.